The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1320
September 7, 2009
View Complete Issue         Table of Contents 2019 
Calcitriol (Vectical) for Mild to Moderate Plaque Psoriasis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Calcitriol (Vectical) for Mild to Moderate Plaque Psoriasis
September 7, 2009 (Issue: 1320)
The FDA has approved calcitriol ointment (Vectical - Galderma), a vitamin D analog, for topical treatment of mild-to-moderate plaque psoriasis in adults ≥18 years old. Ointments are generally considered more potent than creams or solutions.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Calcitriol (Vectical) for Mild to Moderate Plaque Psoriasis
Article code: 1320b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.